This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.

Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)



3B Pharmaceuticals (3BP) is a leader in peptide-based drug discovery and development. The company's core expertise is ranging from hit identification to early clinical development. 3BP's technologies have been validated in projects with industrial and academic partners. Besides ongoing peptide drug discovery partnerships 3BP is developing proprietary targeted radiopharmaceuticals (oncology) and synthetic affinity ligands for protein downstream processing.
4SC (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for the treatment of diseases with a high unmet medical need in various cancer and autoimmune indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.

Founded in 1997, 4SC currently has 83 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

4SC Discovery GmbH is a fully owned subsidiary of 4SC. It was incepted in December 2011 in order to provide fully integrated drug discovery services and innovative preclinical products from idea to IND.
North Rhine-Westphalia
A2M (academia to market) Pharmaceuticals is a spin-off of Schwarz Pharma that is developing the Schwarz CNS portfolio following the merger with UCB. A2M Pharma project portfolio focusses on the therapeutic areas central nervous system and pain. The company develops these projects until clinical proof of concept (POC, clinical phase IIa) which will then be outlicensed or partnered to pharma companies.
ABNOBA GmbH is engaged in manufacture and realization of preparations on a basis of white mistletoe, positioned under general brand AbnobaVISCUM. About 72 different mistletoe preparations are sold world-wide under the brand name abnobaVISCUM. The company manufactures and sells injection drugs for use in oncology and reaches in all areas of sales for herbal oncology a market position among the top three suppliers. The company is involved in basic and clinical research in the field of herbal medicines.
ACROVIS is a privately-held biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of human diseases for which current therapy is either lacking or ineffective. The company specialises in small molecule drugs with novel mechanisms of action.The lead product candidate ACR-488 is a first-in-class small molecule for cancer treatment. The company's proprietary in-house therapeutics programs focus on liver and kidney diseases.
Activaero is a respiratory area specialist, utilizing its proprietary flow and volume controlled inhalation approach FAVORITE to develop novel, pharmacoeconomically meaningful therapies for patients with severe lung diseases.
Adrenomed AG is a virtual biopharmaceutical company with projects in advanced preclinical-stage. Their mission is to develop drugs that reduce the mortality in life-threatening acute care conditions with high unmet need and limited treatment options.

They discovered the new principle of modulating antibodies, which act as partial inhibitors and thus balance the downstream response and controls bioactivity. This new antobody principle is representing a new class of drugs with an favourable safety profile and broad therapeutic window.

Their lead compound Adrecizumab is a first-in-class humanized monoclonal antibody against Adrenomedullin with excellent preclinical efficacy in acute kidney injury and sepsis and a good tolerability.
AET BioTech is a partner for the collaborative development of biosimilars. Built on a 50 year success story of the oldest player in the field of generics, the AET Group (Alfred E. Tiefenbacher GmbH & Co. KG), AET BioTech benefits from exceptional experience in scientific, legal and technical fields and leverages its specific know-how in joint development programs, taking biosimilars from concept to worldwide registration and supplying to leading pharmaceutical brands.
Frankfurt am Main
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds from drug discovery to regulatory approval.

The company?s innovative approach of "personalized medicine" means tailoring treatments to a patient?s specific condition and to unmet medical needs. The company has submitted a NDA to the US FDA for its oral ghrelin agonist, macimorelin acetate (AEZS-130). The compound has the potential to become the first approved product that induces GH release to evaluate adult growth hormone deficiency (AGHD). Its product pipeline encompasses about half a dozen compounds in clinical trials and as many in preclinical development.
Affimed is a clinical stage biotech company developing unique TandAb
Agennix AG is a publicly traded biopharmaceutical company that is focused on the development of novel therapies to improve the length and quality of life of seriously ill patients in areas of major unmet medical need. Company?s clinical development programs include oral talactoferrin alfa; a topical gel form of talactoferrin and RGB-286638, a multi-targeted kinase inhibitor.
North Rhine-Westphalia
AiCuris is a biopharma company focused on the discovery, research and clinical development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. As AiCuris is dedicated to innovation in the field of anti-infective drugs, nearly all of AiCuris compounds stem from novel chemical classes and are directed against novel targets. AiCuris compounds therefore are resistance-breaking by design.